{"id":"https://openalex.org/W1890948742","doi":"https://doi.org/10.1038/bcj.2015.38","title":"Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma","display_name":"Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma","publication_year":2015,"publication_date":"2015-05-15","ids":{"openalex":"https://openalex.org/W1890948742","doi":"https://doi.org/10.1038/bcj.2015.38","mag":"1890948742","pmid":"https://pubmed.ncbi.nlm.nih.gov/25978432","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4476017"},"language":"en","primary_location":{"id":"doi:10.1038/bcj.2015.38","doi":"https://doi.org/10.1038/bcj.2015.38","is_oa":true,"landing_page_url":"https://doi.org/10.1038/bcj.2015.38","pdf_url":"https://www.nature.com/articles/bcj201538.pdf","source":{"id":"https://openalex.org/S2496263508","display_name":"Blood Cancer Journal","issn_l":"2044-5385","issn":["2044-5385"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Journal","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.nature.com/articles/bcj201538.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091207345","display_name":"Teru Hideshima","orcid":"https://orcid.org/0000-0003-2939-6224","observed_orcids":["https://orcid.org/0000-0003-2939-6224"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T Hideshima","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034020009","display_name":"Francesca Cottini","orcid":"https://orcid.org/0000-0001-8676-7840","observed_orcids":["https://orcid.org/0000-0001-8676-7840"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F Cottini","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040386659","display_name":"Hiroto Ohguchi","orcid":"https://orcid.org/0000-0001-8461-7398","observed_orcids":["https://orcid.org/0000-0001-8461-7398"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H Ohguchi","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065898212","display_name":"Jana Jakub\u0131\u0301kov\u00e1","orcid":"https://orcid.org/0000-0003-2593-569X","observed_orcids":["https://orcid.org/0000-0003-2593-569X"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J Jakubikova","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049134468","display_name":"G\u00fcll\u00fc G\u00f6rg\u00fcn","orcid":"https://orcid.org/0000-0001-9875-8394","observed_orcids":["https://orcid.org/0000-0001-9875-8394"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G Gorgun","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048967405","display_name":"Naoya Mimura","orcid":"https://orcid.org/0000-0002-1717-9428","observed_orcids":["https://orcid.org/0000-0002-1717-9428"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N Mimura","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110335844","display_name":"YT Tai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Y-T Tai","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045740077","display_name":"Nikhil C. Munshi","orcid":"https://orcid.org/0000-0002-7344-9795","observed_orcids":["https://orcid.org/0000-0002-7344-9795","https://orcid.org/0000-0002-8397-100X"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N C Munshi","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P G Richardson","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"K C Anderson","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5032464400"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"],"apc_list":{"value":5290,"currency":"USD","value_usd":5290},"apc_paid":{"value":5290,"currency":"USD","value_usd":5290},"fwci":8.4816,"has_fulltext":true,"cited_by_count":65,"citation_normalized_percentile":{"value":0.98002959,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":90,"max":100},"biblio":{"volume":"5","issue":"5","first_page":"e312","last_page":"e312"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.9789999723434448},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.9580000042915344},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/thalidomide","display_name":"thalidomide","score":0.8349999785423279},{"id":"https://openalex.org/keywords/pomalidomide","display_name":"pomalidomide","score":0.9909999966621399},{"id":"https://openalex.org/keywords/cereblon","display_name":"cereblon","score":0.8880000114440918},{"id":"https://openalex.org/keywords/c-myc","display_name":"c-Myc","score":0.8970000147819519},{"id":"https://openalex.org/keywords/entinostat","display_name":"entinostat","score":0.7590000033378601},{"id":"https://openalex.org/keywords/vorinostat","display_name":"vorinostat","score":0.9710000157356262},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6710000038146973},{"id":"https://openalex.org/keywords/synergistic-cytotoxicity","display_name":"synergistic cytotoxicity","score":0.9269999861717224},{"id":"https://openalex.org/keywords/hdac6-inhibition","display_name":"HDAC6 inhibition","score":0.6079999804496765}],"concepts":[{"id":"https://openalex.org/C2778540781","wikidata":"https://www.wikidata.org/wiki/Q21112029","display_name":"Cereblon","level":5,"score":0.9036283493041992},{"id":"https://openalex.org/C2778524551","wikidata":"https://www.wikidata.org/wiki/Q7227206","display_name":"Pomalidomide","level":4,"score":0.791851282119751},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.717788577079773},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.685238778591156},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.6635918617248535},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.6373262405395508},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.6346554160118103},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5826818943023682},{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.5732468366622925},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5468218326568604},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5373856425285339},{"id":"https://openalex.org/C2776202225","wikidata":"https://www.wikidata.org/wiki/Q3569101","display_name":"Histone deacetylase inhibitor","level":5,"score":0.47428804636001587},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.46896564960479736},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.28195130825042725},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.21743181347846985},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.19173213839530945},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15295031666755676},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.09415873885154724},{"id":"https://openalex.org/C25602115","wikidata":"https://www.wikidata.org/wiki/Q407111","display_name":"Ubiquitin","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C134459356","wikidata":"https://www.wikidata.org/wiki/Q4274835","display_name":"Ubiquitin ligase","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077337","descriptor_name":"Vorinostat","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005434","descriptor_name":"Flow Cytometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006877","descriptor_name":"Hydroxamic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D014162","descriptor_name":"Transfection","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015151","descriptor_name":"Immunoblotting","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020133","descriptor_name":"Reverse Transcriptase Polymerase Chain Reaction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D034741","descriptor_name":"RNA, Small Interfering","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056572","descriptor_name":"Histone Deacetylase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D056747","descriptor_name":"Immunomodulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D066298","descriptor_name":"In Vitro Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1038/bcj.2015.38","doi":"https://doi.org/10.1038/bcj.2015.38","is_oa":true,"landing_page_url":"https://doi.org/10.1038/bcj.2015.38","pdf_url":"https://www.nature.com/articles/bcj201538.pdf","source":{"id":"https://openalex.org/S2496263508","display_name":"Blood Cancer Journal","issn_l":"2044-5385","issn":["2044-5385"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Journal","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4476017","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4476017","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer J","raw_type":"Text"},{"id":"pmid:25978432","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25978432","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood cancer journal","raw_type":"Journal Article"},{"id":"pmh:oai:dash.harvard.edu:1/17295776","doi":null,"is_oa":true,"landing_page_url":"http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295776","pdf_url":null,"source":{"id":"https://openalex.org/S4306401540","display_name":"Digital Access to Scholarship at Harvard (DASH) (Harvard University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I136199984","host_organization_name":"Harvard University","host_organization_lineage":["https://openalex.org/I136199984"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1038/bcj.2015.38","doi":"https://doi.org/10.1038/bcj.2015.38","is_oa":true,"landing_page_url":"https://doi.org/10.1038/bcj.2015.38","pdf_url":"https://www.nature.com/articles/bcj201538.pdf","source":{"id":"https://openalex.org/S2496263508","display_name":"Blood Cancer Journal","issn_l":"2044-5385","issn":["2044-5385"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Journal","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9907000064849854}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1894633412","display_name":null,"funder_award_id":"R01-CA178264","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G3549977710","display_name":"Host-tumor cell interaction in myeloma: therapeutic applications","funder_award_id":"5p01ca078378-15","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G4680808690","display_name":null,"funder_award_id":"P01-CA078378","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G4933731489","display_name":"SPORE in Multiple Myeloma","funder_award_id":"P50CA100707","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G5276536440","display_name":"Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications","funder_award_id":"R01CA050947","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G6820238456","display_name":"Functional and biologic significance of deacetylase3 inhibition in myeloma","funder_award_id":"5r01ca178264-05","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1890948742.pdf","grobid_xml":"https://content.openalex.org/works/W1890948742.grobid-xml"},"referenced_works_count":44,"referenced_works":["https://openalex.org/W1537559901","https://openalex.org/W1966864702","https://openalex.org/W1969648097","https://openalex.org/W1982415141","https://openalex.org/W1985093548","https://openalex.org/W1986297232","https://openalex.org/W1986743724","https://openalex.org/W1997952190","https://openalex.org/W1999964913","https://openalex.org/W2003820822","https://openalex.org/W2004288940","https://openalex.org/W2005100560","https://openalex.org/W2010552629","https://openalex.org/W2011694089","https://openalex.org/W2015345028","https://openalex.org/W2021199187","https://openalex.org/W2025656486","https://openalex.org/W2046345187","https://openalex.org/W2047698397","https://openalex.org/W2048722552","https://openalex.org/W2052169053","https://openalex.org/W2055028613","https://openalex.org/W2063827408","https://openalex.org/W2066713758","https://openalex.org/W2068412287","https://openalex.org/W2082168562","https://openalex.org/W2083784041","https://openalex.org/W2094112670","https://openalex.org/W2095026025","https://openalex.org/W2097774235","https://openalex.org/W2104244233","https://openalex.org/W2104373533","https://openalex.org/W2120572492","https://openalex.org/W2131574772","https://openalex.org/W2133590787","https://openalex.org/W2149386327","https://openalex.org/W2152065071","https://openalex.org/W2162934657","https://openalex.org/W2166427186","https://openalex.org/W2173387122","https://openalex.org/W2430507127","https://openalex.org/W2530681607","https://openalex.org/W2564114766","https://openalex.org/W2565245568"],"related_works":["https://openalex.org/W2952304238","https://openalex.org/W2281063473","https://openalex.org/W3112350425","https://openalex.org/W2593366496","https://openalex.org/W2084600223","https://openalex.org/W2584148742","https://openalex.org/W2336228478","https://openalex.org/W3033685607","https://openalex.org/W1741438581","https://openalex.org/W2985466344"],"abstract_inverted_index":{"Immunomodulatory":[0],"drugs":[1],"(IMiDs)":[2],"thalidomide,":[3],"lenalidomide":[4],"(Len)":[5],"and":[6,18,23,174],"pomalidomide":[7],"trigger":[8,39],"anti-tumor":[9],"activities":[10],"in":[11,152,165],"multiple":[12],"myeloma":[13],"(MM)":[14],"by":[15,45,90,102],"targetting":[16],"cereblon":[17,80],"thereby":[19],"impacting":[20],"IZF1/3,":[21],"c-Myc":[22],"IRF4.":[24],"Histone":[25],"deacetylase":[26],"inhibitors":[27],"(HDACi)":[28],"also":[29],"downregulate":[30],"c-Myc.":[31,49,72],"We":[32],"therefore":[33],"determined":[34],"whether":[35],"IMiDs":[36],"with":[37,54,69,99,110,118,125,154,167],"HDACi":[38,56,164],"significant":[40],"MM":[41,97,129,150],"cell":[42],"growth":[43],"inhibition":[44,144],"inhibiting":[46],"or":[47,60],"downregulating":[48],"Combination":[50],"treatment":[51,95,109],"of":[52,71,79,86,96,133],"Len":[53,103,126,168],"non-selective":[55],"suberoylanilide":[57],"hydroxamic":[58],"acid":[59],"class-I":[61,122,142],"HDAC-selective":[62],"inhibitor":[63,117],"MS275":[64,100],"induces":[65,127],"synergic":[66],"cytotoxicity,":[67],"associated":[68],"downregulation":[70,173],"Unexpectedly,":[73],"we":[74],"observed":[75],"that":[76,139],"decreased":[77],"levels":[78],"(CRBN),":[81],"a":[82],"primary":[83],"target":[84],"protein":[85],"IMiDs,":[87],"was":[88],"triggered":[89],"these":[91],"agents.":[92],"Indeed,":[93],"sequential":[94],"cells":[98],"followed":[101],"shows":[104],"less":[105],"efficacy":[106],"than":[107],"simultaneous":[108],"this":[111],"combination.":[112],"Importantly":[113],"ACY1215,":[114],"an":[115],"HDAC6":[116],"minimal":[119],"effects":[120],"on":[121],"HDACs,":[123],"together":[124],"synergistic":[128,149],"cytotoxicity":[130,151],"without":[131],"alteration":[132],"CRBN":[134,172],"expression.":[135],"Our":[136],"results":[137],"showed":[138],"only":[140],"modest":[141],"HDAC":[143],"is":[145],"able":[146],"to":[147,169],"induce":[148],"combination":[153,166],"Len.":[155],"These":[156],"studies":[157],"may":[158],"provide":[159],"the":[160],"framework":[161],"for":[162],"utilizing":[163],"both":[170],"avoid":[171],"enhance":[175],"anti-MM":[176],"activities.":[177]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":14},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}